Brekiya Now Available for Migraine and Cluster Headache Treatment
Brekiya, a ready-to-use dihydroergotamine (DHE) autoinjector, is now available for the acute treatment of migraine with or without aura and cluster headaches in adults.
Brekiya is supplied as a 1mL prefilled single-dose autoinjector containing 1mg/mL of DHE, an ergotamine derivative, which works by agonist effects at 5-HT1D receptors in patients with migraine.
As the first and only self-administered, ready-to-use DHE autoinjector, Brekiya offers patients the ability to treat debilitating attacks in a convenient way and avoid visits to the emergency room.
Brekiya does not require refrigeration, assembly, or priming of the device, making it a convenient treatment option.
Author summary: Brekiya is a new treatment for migraines and cluster headaches.
More News
- AI-Powered Automation: The Key To Growing Your Business Faster
- Mawani, CMA CGM sign SAR 1.7B deal to develop Jeddah port terminal - Shipping Herald
- DigiKey Grows Inventory with Over 31,000 New Stocking Parts in Q3 2025
- Chicago Teachers Union spent $173K on poolside recording studio, won’t show audit to members
- Conservation charity goes into liquidation amid financial problems
- Stella Sora is celebrating Halloween with its first-ever event featuring an adventure at sea
- Why Malaysia's Gig Workers Bill entrenches workers' dependency, not protection - Aliran